A Phase 1a/1b dose escalation, dose expansion study of SW-682 in participants with advanced solid tumors enriched for those with Hippo pathway mutations.

MC #24-16

NCT #
Condition(s)
Mesothelioma, Solid Tumor
Molecular Target(s)
TEAD
Drug Classification(s)
Small Molecule Inhibitor
Agents(s)
SW-682
Phase(s)
I

Mechanism of Action

SW-682 is a TEAD inhibitor

Purpose

In this study, the sponsor and investigators want to learn:
• How much of the study drug can be given with an acceptable level of side effects
• The effects of the study drug (good and bad)
• How much of the study drug is absorbed into the blood and how fast it is removed
• If research tests can be used in the future to predict who will benefit from SW-682
• How the study drug is acting on your body

Study Design

This is a dose escalation/expansion study. The study regimen will be given in cycles. Each cycle is 28 days long. You will receive the study drug as a tablet to be taken daily by mouth. The study drug should be taken with about 1 cup of water. Do not eat any food from at least 2 hours before until at least 1 hour after taking the study drug.

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000